肿瘤药物研究的临床成功率为心血管疾病药物的1/3。肿瘤仍然具有分布广泛和致命性的特征。尽管研究机构很多,但治疗结果方面,疾病的总体改善率仍然不令人满意。抗肿瘤策略研究即显得尤为重要。对于抗癌药物靶点,必须区别必要靶点和非必要的靶点。针对于必要靶点,特异性抑制剂可 The clinical success rate of oncology drug research is one third of that of cardiovascular disease drugs. Tumors still have a widespread and fatal character. Despite the large number of research institutes, the overall rate of improvement of the disease remains unsatisfactory in terms of treatment outcomes. Antitumor strategy research is particularly important. For anticancer drug targets, the necessary and non-essential targets must be distinguished. Specific inhibitors can be targeted for the desired target